# NCT04209114 (NCT04209114)

> A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: bempegaldesleukin plus nivolumab; nivolumab
- Indication: cisplatin-ineligible muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04209114
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Bladder Cancer; Bladder Tumor; Muscle-Invasive Bladder Cancer
- Interventions: Nivolumab; Radical cystectomy (RC); Bempegaldesleukin
- Enrollment: 114
- Primary outcome: Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care
- Primary outcome: Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care

## Indexed commentary on NCT04209114 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04209114